What the trial was testing
The SORAYA enrolled 106 patients with ovarian cancer. The study was sponsored by ImmunoGen, Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
32% of patients with hard-to-treat ovarian cancer responded to this targeted antibody-drug treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023 · NCT04296890
These findings — that about one in three patients saw their tumors shrink with this targeted treatment — were published in the Journal of clinical oncology : official journal of the American Society of Clinical Oncology and represent the headline result of the study.
Researchers tracked outcomes across 106 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with ovarian cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Mirvetuximab soravtansine received FDA approval in 2022 for platinum-resistant ovarian cancer with high folate receptor alpha expression. If you have ovarian, fallopian tube, or peritoneal cancer that hasn't responded to platinum therapy, ask your oncologist about testing for folate receptor alpha and whether this treatment is right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open ovarian cancer trials
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
The purpose of this study is to test the impact of a multilevel decision support intervention on informed decisions about breast MRI among high-risk Black and Latina women. Participants (N=80) will be randomized to (1) enhanced usual care (risk assessment + referral to nurse practitioner) or (2) decision support (enhanced usual care + decision aid). Assessments will take place at baseline (T0) and 1-month post-intervention (T1). The primary outcome is informed decisions about breast MRI at T1.
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.